AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

By Nikita Chaurasia  | Date: 2021-03-23

AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

The COVID-19 vaccine co-developed by AstraZeneca Plc, a British-Swedish multinational biotechnology company, and scientists at Oxford University, has reportedly passed the U.S. clinical trials with 79% effectiveness in preventing symptomatic disease in over 32,000 participants.

AstraZeneca announced that it would keep analyzing data and make relevant provisions in a bid to request emergency use authorization (EUA) in the United States in the upcoming weeks. The move, if approved by authorities, will make the vaccine available for American citizens.

The shot has already been widely administered across several European countries. The U.S. trials, however, involved a sample size study of 32,000 participants - the largest-ever number of people to be studied for the effectiveness of AstraZeneca’s COVID-19 vaccine.

The study could reinstate public confidence in the vaccine, after speculations regarding its efficacy arose following serious blood-clotting issues in a small number of individuals in Europe who received the shot, sources claimed. The trials conducted in the U.S. found no increased risk of serious blood clotting among the vaccinated population.

AstraZeneca reportedly mentioned that the vaccine had an 80% rate of efficacy among elder participants aged 65 years and above.

In the past few weeks, blood clotting fears led several European countries, such as Italy and Germany, to temporarily discontinue the use of the vaccine. However, most countries resumed its usage after European and U.K. medicine authorities reiterated the shot's effectiveness despite the rare incidences of blood clotting, which were not proven to be connected to the vaccine.

The EU regulators claimed to not have ruled out the possibility of blood clots but emphasized that the vaccine is a shield preventing severe symptoms and death and that its benefits outweigh risks.

In other news, AstraZeneca has recently cut the number of doses delivered to the EU after blaming production delays in the Netherland and Belgium. The EU had imposed export controls for coronavirus vaccines in March this year to stop a consignment of 2,50,000 doses that were to be shipped from Italy to Australia.

Source Credits –

https://www.marketwatch.com/story/astrazeneca-us-covid-vaccine-trial-79-effective-2021-03-22?link=MW_latest_news

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Zomato net loss triples to USD 46 million despite 75% jump in revenues

Zomato net loss triples to USD 46 million despite 75% jump in revenues

By Nikita Chaurasia

Indian food delivery giant Zomato Limited has reported a net loss worth USD 46 million in Q4 of FY2021-22 despite witnessing a 75% growth in revenue to USD 156 million as opposed to USD 89 million it earlier recorded during the fourth quarter of the ...

Facebook-owner Meta to share more data on political advertisements

Facebook-owner Meta to share more data on political advertisements

By Nikita Chaurasia

Facebook-parent Meta Platforms Inc has recently announced that it would provide additional data from its public ad database regarding the targeting decisions made by publishers running social and political-issue advertising. As a part of the expan...

Massachusetts finds first 2022 monkeypox case in the United States

Massachusetts finds first 2022 monkeypox case in the United States

By Nikita Chaurasia

The Massachusetts Department of Public Health has recently reported the first case of a rare infection called monkeypox in a man who recently visited Canada. According to Boston’s public department, the identified case is no threat to the pu...

Russia denies plans of blocking YouTube & cutting off from the internet

Russia denies plans of blocking YouTube & cutting off from the internet

By Nikita Chaurasia

The Digital Development Minister of Russia has reportedly stated that the country is not planning to block Google’s video streaming platform YouTube as such a move would affect its users and will therefore be avoided.  It is worth notin...

Indian food delivery giant Swiggy to buy Dineout from Times Internet

Indian food delivery giant Swiggy to buy Dineout from Times Internet

By Nikita Chaurasia

Swiggy, an Indian food delivery giant, has recently announced an agreement with Times Internet to buy Dineout, a dining and restaurant technology platform. Swiggy will use the acquisition to enter the dining out (non-delivery) market, where it will c...